About Us

Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise to build highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital and the support from some of the most prestigious limited partners in the world, Decheng is poised to create value for our investors and entrepreneur partners.


Founded in 2012

Asset Under Management

$2.1 billion of capital

Your Partner

Preferred partners for entrepeneurs, world-class scientists and strategic partners

Recent News

May 9 2024

Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing

April 25, 2024

Regeneron Signs Mammoth Gene Editing Deal Worth $100M Upfront

April 22, 2024

Bristol Myers Signs $380 Million CAR-T Therapies Supply Deal with Cellares


August 23, 2023

Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO)                                               

June 8, 2023

Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases                                   

April 16, 2023

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences for $10.8 Billion